Atrial septal defect occluders: Difference between revisions
(New page: {{Atrial septal defect}} {{CMG}}; '''Associate Editors-In-Chief:''' Priyamvada Singh, MBBS mailto:psingh@perfuse.org; {{CZ}}; '''Assistant Editor-In-Chief:''' [[Kr...) |
m (Bot: Adding CME Category::Cardiology) |
||
(4 intermediate revisions by 2 users not shown) | |||
Line 1: | Line 1: | ||
{{Atrial septal defect}} | {{Atrial septal defect}} | ||
{{CMG}}; '''Associate Editors-In-Chief:''' [[Priyamvada Singh|Priyamvada Singh, MBBS]] [[mailto: | {{CMG}}; '''Associate Editors-In-Chief:''' [[Priyamvada Singh|Priyamvada Singh, MBBS]] [[mailto:psingh13579@gmail.com]]; {{CZ}}; '''Assistant Editor-In-Chief:''' [[Kristin Feeney|Kristin Feeney, B.S.]] [[mailto:kfeeney@elon.edu]] | ||
==Overview== | ==Overview== | ||
Percutaneous transcatheter closure is used in limited atrial septal defect cases. The Food and Drug Administration has only authorized the use of percutaneous closure in [[Atrial septal defect ostium secundum|ostium secundum]] patients. | Percutaneous transcatheter closure is used in limited atrial septal defect cases. The Food and Drug Administration has only authorized the use of percutaneous closure in [[Atrial septal defect ostium secundum|ostium secundum]] patients. | ||
==The Food and Drug Administration authorized Occluders== | |||
The Food and Drug Administration has authorized the following percutaenous transcatheters for usage:<ref name="pmid11829678">{{cite journal| author=Schwetz BA| title=From the Food and Drug Administration. | journal=JAMA | year= 2002 | volume= 287 | issue= 5 | pages= 578 | pmid=11829678 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11829678 }} </ref> | The Food and Drug Administration has authorized the following percutaenous transcatheters for usage:<ref name="pmid11829678">{{cite journal| author=Schwetz BA| title=From the Food and Drug Administration. | journal=JAMA | year= 2002 | volume= 287 | issue= 5 | pages= 578 | pmid=11829678 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11829678 }} </ref> | ||
*Amplatzer septal occluder | *Amplatzer septal occluder | ||
Line 11: | Line 12: | ||
*HELEX septal occluder | *HELEX septal occluder | ||
*Sideris patch | *Sideris patch | ||
==References== | |||
{{reflist|2}} | |||
{{WH}} | |||
{{WS}} | |||
[[CME Category::Cardiology]] | |||
[[Category:Cardiology]] | |||
[[Category:Congenital heart disease]] | |||
[[Category:Pediatrics]] | |||
[[Category:Mature chapter]] |
Latest revision as of 01:59, 15 March 2016
Atrial Septal Defect Microchapters | |
Treatment | |
---|---|
Surgery | |
| |
Special Scenarios | |
Case Studies | |
Atrial septal defect occluders On the Web | |
American Roentgen Ray Society Images of Atrial septal defect occluders | |
Risk calculators and risk factors for Atrial septal defect occluders | |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editors-In-Chief: Priyamvada Singh, MBBS [[2]]; Cafer Zorkun, M.D., Ph.D. [3]; Assistant Editor-In-Chief: Kristin Feeney, B.S. [[4]]
Overview
Percutaneous transcatheter closure is used in limited atrial septal defect cases. The Food and Drug Administration has only authorized the use of percutaneous closure in ostium secundum patients.
The Food and Drug Administration authorized Occluders
The Food and Drug Administration has authorized the following percutaenous transcatheters for usage:[1]
- Amplatzer septal occluder
- CardioSEAL
- HELEX septal occluder
- Sideris patch
References
- ↑ Schwetz BA (2002). "From the Food and Drug Administration". JAMA. 287 (5): 578. PMID 11829678.